Ascendis Pharma AS (STU:A71) Total Liabilities : €1,285.2 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma AS Total Liabilities?

Ascendis Pharma AS's Total Liabilities for the quarter that ended in Dec. 2024 was €1,285.2 Mil.

Ascendis Pharma AS's quarterly Total Liabilities increased from Jun. 2024 (€1,079.43 Mil) to Sep. 2024 (€1,191.10 Mil) and increased from Sep. 2024 (€1,191.10 Mil) to Dec. 2024 (€1,285.20 Mil).

Ascendis Pharma AS's annual Total Liabilities increased from Dec. 2022 (€826.39 Mil) to Dec. 2023 (€971.28 Mil) and increased from Dec. 2023 (€971.28 Mil) to Dec. 2024 (€1,285.20 Mil).

Ascendis Pharma AS Total Liabilities Historical Data

The historical data trend for Ascendis Pharma AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Total Liabilities Chart

Ascendis Pharma AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

141.08

201.29

826.39

971.28

1,285.20

Ascendis Pharma AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															971.28	1,040.68	1,079.43	1,191.10	1,285.20

Ascendis Pharma AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ascendis Pharma AS's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	907.863	+	(365.08	+	-1.7763568394003E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	12.258	+	0	+	0)
	=	1,285.2

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1179.495	-	-105.706
	=	1,285.2

Ascendis Pharma AS's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	907.863	+	(365.08	+	-1.7763568394003E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	12.258	+	0	+	0)
	=	1,285.2

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1179.495	-	-105.706
	=	1,285.2

Ascendis Pharma AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (STU:A71) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ASND:USA ASND:Mexico A71:Germany A1SN34:Brazil

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

https://www.ascendispharma.com

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma AS Headlines

No Headlines